Genprex Demonstrates Growth and Expansion Through Recent Achievements
August 13 2019 - 08:00AM
Business Wire
Company’s recent performance sets path for
future milestones, commercialization
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy
company, today announced recent achievements the company has
completed as a part of the company’s overall strategy to expand its
clinical development programs and bring its lead drug candidate,
Oncoprex™ immunogene therapy, to commercialization.
These recent achievements are outlined in the company’s newly
launched, interactive corporate timeline, which can be found on
Genprex’s website.
“Since Genprex’s IPO last year, we have made significant
progress in many areas of the company, including progress toward
expansion of our clinical programs and sponsored research, our
manufacturing process development and scalability, and the growth
of our team to support these initatives,” said Rodney Varner,
Chairman and Chief Executive Officer of Genprex. “These
accomplishments have set the stage for us to continue on our path
of growth and expansion, enabling our efforts to bring our drug
candidate to market for lung cancer patients who cannot benefit
from today’s therapies.”
Genprex’s updates to ongoing activities, include:
Q2 2019
- Announced positive pre-clinical findings from MD Anderson
Cancer Center Sponsored Research Agreement studying the effects of
TUSC2 with pembrolizumab at American Association of Cancer Research
meeting
- Developed Oncoprex and immunotherapy combination clinical trial
design
- Collaborated with Addison Whitney for drug nomenclature
branding program and submission of non-proprietary drug name
selections
- Initiated manufacturing process development with key
manufacturing partners to support clinical expansion and
manufacturing scale-up processes
- Completed manufacturing of TUSC2 DNA plasmid to support
clinical trial ramp-up
Q1 2019
- Appointed Key Staff: Senior Director of Pharmaceutical Sciences
and Manufacturing and Senior Manager of Communications and
Marketing
- USPTO issued two additional patents to add to our intellectual
property portfolio
- Identified potential new clinical sites for expansion of
Oncoprex and erlotinib combination clinical trial
Q4 2018
- Appointed Key Staff: VP of Clinical Operations
- Completion of clinical data reconciliation within a
CDISC/SDTM-compliant database
Q3 2018
- Initiated clinical site selection and expansion program with
CRO partner
- Initialization of sponsored pre-clinical research with MD
Anderson Cancer Center to evaluate TUSC2 with immunotherapies
including immune checkpoint inhibitors anti-PD1 and CTLA-4
Q2 2018
- Continued execution and enhancement of strategy for
manufacturing technology transfer and scale-up initiatives
Genprex’s new interactive timeline on its website shares
additional historical achievements, where visitors can follow the
company’s success since its inception.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. For more information, please visit the company’s web
site at www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effects of Oncoprex on cancer and our ability to continue to
grow and expand our business and to bring our drug candidates to
market. Risks and uncertainties that contribute to the uncertain
nature of the forward-looking statements include the presence and
level of TUSC2’s effect on cancer, the timing and success of our
clinical trials and planned clinical trials of TUSC2 and Oncoprex™
and our other potential product candidates and the timing and
success of obtaining FDA approval of Oncoprex™ and our other
potential product candidates. These and other risks and
uncertainties are described more fully under the caption “Risk
Factors” and elsewhere in our filings and reports with the United
States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. We undertake no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190813005036/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Genprex Media Relations Kalyn Dabbs (877) 774-GNPX
(4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2023 to Mar 2024